Linked Life Data

3913221

Source:http://linkedlifedata.com/resource/pubmed/id/3913221

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
1986-4-11
pubmed:abstractText
Animal experiments have demonstrated a synergistic immunosuppressive effect when using the combination of ciclosporin (CS) and azathioprine (AZA) as immunosuppressant. On this basis these drugs were used in patients considered to be at high risk for immunological complications. Group I (immunological risk patients) consisted of 63 patients with a second or third graft and/or elevated cytotoxic antibodies above 30% against the test panel. In addition to the basic immunosuppressive therapy (CS) and methylprednisolone (MP), AZA was given in the first 2 weeks following transplantation. Group II (historical control) summarized immunological risk patients with conventional immunosuppressive therapy (AZA/MP). The IIIrd group with 28 patients on the above mentioned immunological risk were treated with CS and MP only. The results revealed a 2-year actuarial graft survival rate of 68% (groups I) versus 40% (group II) versus 52% (group III). There were no differences in WBC and platelet counts or in infectious complications. No malignancy was noticed.
pubmed:language
ger
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0044-3611
pubmed:author
pubmed:issnType
Print
pubmed:volume
78
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
667-71
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1985
pubmed:articleTitle
[Combined immunosuppression (cyclosporin, azathioprine, methylprednisolone) in patients at immunological risk after kidney transplantation].
pubmed:publicationType
Journal Article, Comparative Study, English Abstract